RPQ

Nexalin Technology Announces Positive Results of Clinical Study Validating its Gen-2 tACS Device for Reducing Pain Among Veterans with Mild Traumatic Brain Injury at University of California, San Diego

Retrieved on: 
Thursday, March 28, 2024
MEG, Development, Psychiatry, Veteran, Physician, Post-traumatic stress disorder, NSI, Analysis of variance, Patient, UC, RPQ, Jesse Russell, Radiology, Human services, PCS, Concussion, Trial of the century, University, McGill Pain Questionnaire, Brain damage, Pain, ANOVA, Vaccine, PTSD, MPQ, Medical imaging

HOUSTON, TEXAS, March 28, 2024 (GLOBE NEWSWIRE) -- Nexalin Technology, Inc. (the “Company” or “Nexalin”) (Nasdaq: NXL; NXLIW) today announced the positive results of a clinical study evaluating Nexalin’s Gen-2 tACS device for reducing pain in veteran patients with Mild Traumatic Brain Injury (mTBI). The study was conducted at The University of California, San Diego, and is further detailed in an abstract co-authored by the United States Department of Veterans Affairs (VA) San Diego Healthcare System, and the Radiology, Psychiatry and Neurosciences Departments of UC San Deigo.

Key Points: 
  • mTBI is a leading cause of sustained physical, cognitive, emotional, and behavioral deficits in veterans and the general public.
  • However, the underlying pathophysiology is not completely understood, and there are few effective treatments for post-concussive symptoms (PCS).
  • The study was conducted as a randomized, double-blind, placebo-controlled clinical trial over an eight-week period, with two groups being examined: an active tACS group and a sham tACS group.
  • Mark White, CEO of Nexalin Technology, stated, "We are encouraged by the results of the clinical study, reinforcing the significant reduction in pain and other persistent symptoms of mild traumatic brain injury among veteran patients.

Moleac’s NeuroAiD™II Improves Post-Concussion Symptoms, Quality of Life, and Mood after a Mild Traumatic Brain Injury

Retrieved on: 
Tuesday, December 5, 2023
NeuroAiD, TBI, Concussion, Quality of life, Cognition, Life, SAMURAI, Depression, RPQ, Brain, Incidence, Congress, Headache, Skull, Dizziness, Anxiety, HADS, Death, Brain damage, CNS, Patient, Self-assessment, Computerize, Medical device

SINGAPORE, Dec. 04, 2023 (GLOBE NEWSWIRE) -- Moleac announced promising results from the SAMURAI double-blind study in patients with mild traumatic brain injury (mTBI) receiving a 6-month course of NeuroAiD™II.

Key Points: 
  • SINGAPORE, Dec. 04, 2023 (GLOBE NEWSWIRE) -- Moleac announced promising results from the SAMURAI double-blind study in patients with mild traumatic brain injury (mTBI) receiving a 6-month course of NeuroAiD™II.
  • In the study, the NeuroAiD™II group showed significant improvement in their post-concussion symptoms, quality of life and mood, compared to those in the placebo group.
  • In the SAMURAI study, mTBI patients underwent a series of tests assessing various types of impairments and their recovery over time.
  • For cognition, a self-assessment was done by the patient using a computerized scale, the Computerized Neurocognitive Assessment-Vital Signs (CNS-VS).

ISPE Announces Senior Industry Executives and Global Regulators to Open 2021 ISPE Annual Meeting & Expo

Retrieved on: 
Friday, October 1, 2021
ISPE, Medication, Compliance, WHO, Solution, FDA, World Health Organization, RPQ, Medicine, International Society, ORA, Johnson & Johnson, Janssen Pharmaceuticals, Assistant commissioner, Leadership, Medical device, Regulation, Supply chain, World, Florida, Vaccine, Robin, VP, Pharming, R, Trade, Maryland, Name, US, Association, Animal, Pharmaceutical industry

NORTH BETHESDA, Md., Oct. 1, 2021 /PRNewswire-PRWeb/ -- The International Society for Pharmaceutical Engineering (ISPE) announced the addition of four new keynote presenters for the 2021 ISPE Annual Meeting & Expo .

Key Points: 
  • NORTH BETHESDA, Md., Oct. 1, 2021 /PRNewswire-PRWeb/ -- The International Society for Pharmaceutical Engineering (ISPE) announced the addition of four new keynote presenters for the 2021 ISPE Annual Meeting & Expo .
  • The 2021 ISPE Annual Meeting & Expo features a dynamic line-up of thought-provoking keynote presentations led by some of the most prominent names in the pharmaceutical industry.
  • Elizabeth Miller, Pharm.D, Assistant Commissioner for Medical Products and Tobacco Operations, FDA/ORA
    Dr. Elizabeth Miller recently rejoined the US FDA in March 2020.
  • Robin has responsibility for Quality & Compliance for the Global Pharmaceuticals Segment in Pre-Market R&D, Supply Chain and Post Market Commercial.